3rd Quarter - Report

HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION for HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION

Firm
Client
Income
—
Expenses
$40,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Drug and Medical Device Pedigree, H.R. 5839; DMEPOS and Lab Competitive Bidding, H.R. 6331; Physician Payments Sunshine Act, S. 2029

LobbyistCovered position, as disclosed
AARON FRAZIER Government Affairs Analyst
ADNAN JALIL Government Affairs Director
AMY MICHAEL KOHL Government Affairs Analyst
MATTHEW JAMES ROWAN President and CEO
ANDREW VAN OSTRAND Vice President, Policy and Research

Contacted: SENATE; Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 5839 (110th), H.R. 6331 (110th), S. 2029 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.